Statements (59)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Clinical_Trials
|
gptkbp:aims_to_determine |
safety profile
|
gptkbp:aims_to_improve |
patient outcomes
cost-effectiveness |
gptkbp:analyzes |
demographic data
long-term effects |
gptkbp:business_model |
institutional review board
|
gptkbp:collaborates_with |
academic institutions
multiple sites |
gptkbp:completed |
gptkb:2022
|
gptkbp:conducted |
gptkb:Research_Institute
community engagement multiple countries strict regulatory guidelines |
gptkbp:evaluates |
quality of life
adverse events |
gptkbp:focuses_on |
treatment efficacy
|
https://www.w3.org/2000/01/rdf-schema#label |
CLARITY 3 study
|
gptkbp:includes |
informed consent process
placebo group |
gptkbp:involves |
patients with cardiovascular disease
follow-up assessments |
gptkbp:is_analyzed_in |
advanced statistical techniques
|
gptkbp:is_anticipated_by |
impact future research directions
|
gptkbp:is_collaborative_with |
international research teams
multidisciplinary team |
gptkbp:is_compared_to |
new treatment vs standard care
|
gptkbp:is_designed_to |
address unmet medical needs
|
gptkbp:is_documented_in |
study protocol
|
gptkbp:is_evaluated_by |
independent reviewers
|
gptkbp:is_expected_to |
enhance understanding of disease mechanisms
generate new insights influence clinical guidelines |
gptkbp:is_focused_on |
innovative therapies
patient-centered outcomes |
gptkbp:is_funded_by |
government grants
|
gptkbp:is_led_by |
principal investigator
|
gptkbp:is_monitored_by |
gptkb:data_safety_monitoring_board
|
gptkbp:is_part_of |
clinical research network
larger research initiative |
gptkbp:is_subject_to |
peer review process
|
gptkbp:is_supported_by |
patient advocacy groups
philanthropic donations |
gptkbp:measures |
clinical outcomes
|
gptkbp:presented_by |
medical conferences
|
gptkbp:published_in |
gptkb:academic_journals
|
gptkbp:recruitment |
diverse population
|
gptkbp:registration |
clinical trial registry
|
gptkbp:reports_to |
findings to stakeholders
|
gptkbp:result |
gptkb:2023
|
gptkbp:sponsored_by |
gptkb:pharmaceuticals
|
gptkbp:started_in |
gptkb:2020
|
gptkbp:targets |
specific patient demographics
|
gptkbp:uses |
statistical analysis methods
randomized controlled trial design |
gptkbp:utilizes |
biomarkers
electronic health records |
gptkbp:bfsParent |
gptkb:Mavenclad
|
gptkbp:bfsLayer |
6
|